Thursday, May 2, 2013

The MEANING OF THE MDHonors AWARD for CRBCM.

MEANING OF THE MDHonors AWARD for CRBCM.

The CRBCM would like to thank MDHonors for the Research award given to our Coalition and young clinic (Greater East cancer Center of El Paso Texas).  This award will allow to build our institution's primary steps into the research power house we intend to become.  It will formalize in practical terms (working on a tangible research project) some of our collaboration attempts with the University Medical Center in El Paso, and the UTEP (University of Texas in El Paso).  With this award, the CRBCM will continue to march toward the cure day by day, and with confidence and focused vision.   And with this steady progression, victory is certain.  MDHonors revived our hope in the belief that we still have a chance to succeed if we try hard enough!
The cure is within reach, we got to keep on believing that it is reachable, and not get discouraged by politicians and malicious institutions which are distracting our progress toward the cure! 
We can not thank MDHonors enough ; for now let's go to work as we face international scrutiny and the true challenge of a cure for cancers!

And God Bless CRBCM
La lucha continua !

Dr Kankonde.
CPRIT ASIDE
OUR COALITION WINS AN INTERNATIONAL RESEARCH AWARD
WE ARE ON THE GO!
WHEN POLITICS AND DISCRIMINATION STOPS, WE ARE TRUE CONTENDERS!

Selma Guessous (WorldOne.com) <selma.guessous@worldone.com>
10:51 AM (5 hours ago)

to me
Dear Dr. Kankonde,

We have the pleasure to inform you that you are the winner of the MDH Research Award funding this month for your project: Lung Cancer Biomarker Detection.

You win 10,000USD! Congratulations!

We would like to share this good news to all our MDHonors members, and communicate more about your project on MDHonors. Could you please reply to the interview document attached in this email, and send us a picture of you and one of your team?

In order to receive your prize, could you let us know your bank details ?

Please let me know if you have any question

Thanks in advance and again congratulations !

Best regards,

Selma Guessous
Panel Development Executive
+44 (0)20 3462 1118 ex 1707 | London
selma@mdhonors.com

Description: mdh

===================================================
AND
INTERESTING CLINICAL VISIT AND QUESTION
IS IT TRUE THAT MUIR TORE AND MAY BE ALSO LYNCH SYNDROMES CAN BE EXACERBATED BY EMBREL USE?
WE NEED TO FURTHER INVESTIGATE THIS
CAN A PATIENT WITH RECURRENT SEBACEOUS CANCER OF THE SKIN RECEIVE EMBREL FOR TREATMENT?

The MUIR-TORRE results from alteration in function of mis-match repair genes particularly the MLH1 and the MSH2.  It belongs to the Lynch family of Syndromes affecting mostly the GI track but also many other organs including the brain!
Downstream from the MLH1 are  ATR, BRCA-1, CHEK-2,EXO1, MAX,MSH3, MSH6,P53 genes
AND DOWNSTREAM MLH2  are EXONUCLEASES, PMS2,MSH4,MYC, BLOOM SYNDROME PROTEIN, MBD4 (REMEMBER MBD4 IS UPSTREAM FROM FADD)

One the other side is EMBREL an anti-TNF
where is the intersection ?
RESPONSE TO HYPOXIA
ANGPTL4, ADM
SLC16A3
HER-2 IN BREAST CANCER

FOR AVASTIN RESPONSE.
=============================================================
You need an intact system in place to obtain Avastin action.
1.   Intact ANGPTL4

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Angiopoietin-like 4
Identifiers
Symbols ANGPTL4; ANGPTL2; ARP4; FIAF; HFARP; NL2; PGAR; pp1158
External IDs OMIM605910 MGI1888999 HomoloGene10755 GeneCards: ANGPTL4 Gene
RNA expression pattern
PBB GE ANGPTL4 221009 s at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 51129 57875
Ensembl ENSG00000167772 ENSMUSG00000002289
UniProt Q9BY76 Q9Z1P8
RefSeq (mRNA) NM_001039667 NM_020581
RefSeq (protein) NP_001034756 NP_065606
Location (UCSC) Chr 19:
8.43 – 8.44 Mb
Chr 17:
33.77 – 33.78 Mb

PubMed search [1] [2]
Angiopoietin-related protein 4 is a protein that in humans is encoded by the ANGPTL4 gene.[1][2][3] Alternatively spliced transcript variants encoding different isoforms have been described. This gene was previously referred to as ANGPTL2, HFARP, PGAR, or FIAF but has been renamed ANGPTL4.

This gene is induced under hypoxic (low oxygen) conditions in various cell types and is the target of Peroxisome proliferator-activated receptors. The encoded protein is a serum hormone directly involved in regulating lipid metabolism and also acts as an apoptosis survival factor for vascular endothelial cells.

Clinical significance

The encoded protein may play a role in several cancers and it also has been shown to prevent the metastatic process by inhibiting vascular activity as well as tumor cell motility and invasiveness. ANGPTL4 contributed to tumor growth and protected cells from anoikis, a form of programmed cell death induced when contact-dependent cells detach from the surrounding tissue matrix. ANGPTL4 secreted from tumors can bind to integrins, activating downstream signaling and leading to the production of superoxide to promote tumorigenesis.[5] ANGPTL4 disrupts endothelial cell junctions by directly interacting with integrin, VE-cadherin and claudin-5 in a sequential manner to facilitates metastasis. ANGPTL4 functions as a matricellular protein[6] to facilitates skin wound healing. ANGPTL4-deficient mice exhibit delayed wound reepithelialization with impaired keratinocyte migration. ANGPTL4 inhibits lipoprotein lipase, LPL, by breaking the dimer molecule. ANGPTL4 has been unambiguously established as a potent inhibitor of blood plasma Triglyceride (TG) clearance, causing elevation of plasma TG levels. As a consequence, ANGPTL4 knockout mice have reduced serum triglyceride levels, whereas the opposite is true for mice over-expressing ANGPTL4. The reduction in LPL activity in adipose tissue during fasting is likely caused by increased local production of ANGPTL4. In other tissues such as heart, production of ANGPTL4 is stimulated by fatty acids and may serve to protect cells against excess fat uptake.[7]"

 IF YOU LIKE YOUR PATIENT WITH CANCER, INHIBIT THIS MOLECULE WITH MIGHTY FORCE AND DO THIS PERSISTENTLY. WONDER WHY AVASTIN SHOULD NOT BE STOPPED UNTIL CLEAR EVIDENCE OF FAILURE IS DISPLAYED?  READ THIS AGAIN!   THIS IS A POWERFUL TARGET AND GIVES YOU THE SECRET TO AVASTIN POWERS IN METASTATIC DISEASES!

Decreased expression of this protein has been associated with type 2 diabetes. AND COULD CONTRIBUTE TO WHY LESS CANCERS ARE OBSERVED IN DIABETIC, AND WHY TRIGLYCERIDES GO WILD IN DIABETICS.

GRAY ET AL ADDED:
"Glucocorticoid receptor blockade prevented fasting-induced tissue Angptl4 expression and WAT TG hydrolysis in mice, and TG hydrolysis induced by fasts of 6 or 24 h was greatly reduced in mice lacking Angptl4 (Angptl4(-/-)). Glucocorticoid treatment mimicked the lipolytic effects of fasting, although with slower kinetics, and this too required Angptl4. Thus, fasting-induced WAT TG hydrolysis requires glucocorticoid action and Angptl4."   LOW DOSE PREDNISONE USED IN PROSTATE CANCER PROTOCOLS MAY BE VALUABLE BECAUSE OF THIS!
IT IS ALSO THE KEY TO WHY AVASTIN IS GOOD IN KEEPING PEOPLE FROM MALIGNANT ASCITES.   KNOCK OFF MICE DIE WITH ASCITES ! 
?IS THIS THE SINGLE MOLECULE EXPLAINING FLUID RETENTION OF STEROIDS,  IT MUST CONTRIBUTE I BELIEVE!  CERTAINLY, LIPODYSTROPHY IS EXPLAINED TOO!

2.ADM GENE

IF YOU SEARCH WHY AVASTIN TREATMENT IS COMPLICATED BY HYPERTENSION, WELL IT BLOCK VASODILATORS SUCH AS THE  ADM GENE.

WIKIPEDIA


Receptors of Adrenomedullin

At present AM is believed to function through combinations of the calcitonin receptor like receptor (CALCRL) and receptor activity-modifying proteins (RAMP2) complexes, as well as CGRP receptors. It is worth noting that unlike the classical one ligand-one receptor notion of receptor signalling, the interaction of both Calcitonin receptor-like (CALCRL) and RAMP ( Receptor activity-modifying protein) at the membrane, is required for AM to mediate its action. The outcome of AM stimulation of its receptor is the cellular production of both cyclic AMP (cAMP) and nitric oxide production. Some may find the production of these inside the cell to be at odds, since often they have opposing effects, but as yet, the timing of these effects remains to be studied.[citation needed]

The physiological functions of Adrenomedullin

AM was initially identified as a vasodilator, some have cited this as the most potent endogenous vasodilatory peptide found in the body (Cockcroft et al., 1997). Differences in opinion regarding the ability of AM to relax vascular tone arises from the differences in the model system used (Hamid and Baxter, 2005). Other effects of AM include increasing the tolerance of cells to oxidative stress and hypoxic injury and angiogenesis. AM is seen as a positive influence in diseases such as hypertension, myocardial infarction, chronic obstructive pulmonary disease and other cardiovascular diseases, whereas it can be seen as a negative factor in potentiating the potential of cancerous cells to extend their blood supply and cause cell proliferation."

THIS KNOWLEDGE CAN HELP PICK THE BEST TREATMENT FOR COMPLICATION BY HYPERTENSION DURING AVASTIN USE!   INCIDENTALLY, IT UNVAIL THE RAMP2 AS A SECONDARY TARGET.  REMEMBER PERTURBING TRANSFER OF RECEPTOR IS A VALID THERAPEUTIC INTERVENTION CALLED "MISLOCALIZATION ".

" The protein encoded by this gene is a member of the RAMP family of single-transmembrane-domain proteins, called receptor (calcitonin) activity modifying proteins (RAMPs). RAMPs are type I transmembrane proteins with an extracellular N-terminus and a cytoplasmic C-terminus. RAMPs are required to transport calcitonin-receptor-like receptor (CRLR) to the plasma membrane. CRLR, a receptor with seven transmembrane domains, can function as either a calcitonin gene-related peptide (CGRP) receptor or an adrenomedullin receptor, depending on which members of the RAMP family are expressed. In the presence of this (RAMP2) protein, CRLR functions as an adrenomedullin receptor. The RAMP2 protein is involved in core glycosylation and transportation of adrenomedullin receptor to the cell surface.[1] WIKIPEDIA"

3.ANOTHER MISLOCALIZATION TARGET?  THIS ONE IN THE MEMBRANE!
 Entrez Gene summary for SLC16A3:
Lactic acid and pyruvate transport across plasma membranes is catalyzed by members of the proton-linked monocarboxylate
transporter (MCT) family, which has been designated solute carrier family-16. Each MCT appears to have slightly
different substrate and inhibitor specificities and transport kinetics, which are related to the metabolic
requirements of the tissues in which it is found. The MCTs, which include MCT1 (SLC16A1; MIM 600682) and MCT2
(SLC16A7; MIM 603654), are characterized by 12 predicted transmembrane domains (Price et al., 1998 (PubMed
9425115)).(supplied by OMIM, Mar 2008)
 

Wednesday, May 1, 2013

A novel virus genome discovered in an extreme environment suggests recombination between unrelated groups of RNA and DNA viruses

A novel virus genome discovered in an extreme environment suggests recombination between unrelated groups of RNA and DNA viruses

Geoffrey S Diemer and Kenneth M Stedman*
GO to the article ! 

This story truly deserve the reward given to those scientists
it is the story introducing the 9th law of nature
which is the law of adaptation to unusual conditions by adjusting genetic potential, by the power of recombination, and using cellular heterogeneity, and by activating NF-kB.
cells have an incredible versatility potential if given the time and if the programmed death is not triggered by an overwhelming stimulant... to adapt and develop new function ready to deal with change in the environment.  These changes could be dramatic! ie we lost our tail for god sake!
The reversal of mesenchymal transformation is another of change to adaptation and is the underlying reason of deviation of epithelialization driving the Barrett transformation in the lower 3rd of the Esophagus.  These changes are benign until receptor become desensitized to an overwhelming and relentless stimulation leading to the HSP (heat stroke protein ) gets as well as the provoked!  Prevention of progression to cancer should dampen growth factors and decrease HSP actions!
We have recently hypothesized that the MEK action  as well as the Wnt were membrane located and followed the Reticulum Endothelium tract to reach the nucleus.   With the involvement of the Hedgehog, Basaloid morphology resulted in triple negative breast cancer!  (Again if it is strong enough to induce a morphologic change, it is strong enough to cause an abnormality so significant as a neoplastic process.-even Fanconi abnormality associated with morphology changes (microcephaly) will lead to a Myelodysplastic  Syndrome.  (and we contend that these type of syndrome will respond to Revlimid and Thalidomide type of drugs).  We promise to discuss the gene involved in the 9th law soon but this text tells you already where we are going to fish them!

REMEMBER THE BRCA FAMILY IS NOT THE ONLY DNA REPAIR GENE FAMILY!


1.NBS gene:
============ 
Nijmegen breakage syndrome
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nijmegen breakage syndrome
Classification and external resources
OMIM 251260
DiseasesDB 32395
eMedicine derm/725
MeSH D049932
Nijmegen breakage syndrome (NBS), also known as Berlin breakage syndrome and Seemanova syndrome, is a rare autosomal recessive[1] congenital disorder causing chromosomal instability, probably as a result of a defect in the Double Holliday junction DNA repair mechanism.
NBS1 codes for a protein that has two major functions: (1) to stop the cell cycle in the S phase, when there are errors in the cell DNA (2) to interact with FANCD2 that can activate the BRCA1/BRCA2 pathway of DNA repair. This explains clearly that mutations in the NBS1 gene lead to higher levels of cancer (see Fanconi anemia, Cockayne syndrome...)
The name derives from the Dutch city Nijmegen where the condition was first described.[2]
Most people with NBS have West Slavic origins. The largest number of them live in Poland.
Mrs Seemanova MD after whom the name of the syndrome was given, currently works at Motol Hospital, Prague, Czech Republic, as a Professor of medical genetics.===============================================

2. BLM gene
Bloom syndrome protein is a protein that in humans is encoded by the BLM gene and is not expressed in Bloom syndrome.[1]
The Bloom syndrome gene product is related to the RecQ subset of DExH box-containing DNA helicases and has both DNA-stimulated ATPase and ATP-dependent DNA helicase activities. Mutations causing Bloom syndrome delete or alter helicase motifs and may disable the 3' → 5' helicase activity. The normal protein may act to suppress inappropriate homologous recombination.[2]

Interactions

Bloom syndrome protein has been shown to interact with CHEK1,[3] Replication protein A1,[4][5][6] Werner syndrome ATP-dependent helicase,[7] RAD51L3,[8] Ataxia telangiectasia mutated,[9][10] RAD51,[11] XRCC2,[8] Flap structure-specific endonuclease 1,[12] H2AFX,[3] TP53BP1,[3] FANCM,[13] P53,[3][14][15][16] TOP3A,[4][17][18][19] MLH1[9][18][20][21] and CHAF1A.[22]

TO UNDERSTAND THAT THE BLM GENE IS A DNA REPAIR GENE, YOU MUST REMEMBER WHAT A 'HELICASE' IS:

Helicase

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Structure of E. coli helicase RuvA
DNA helicase
Identifiers
EC number 3.6.4.12
Databases
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum
RNA helicase
Identifiers
EC number 3.6.4.13
Databases
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum
Helicases are a class of enzymes vital to all living organisms. Their main function is to unpackage an organism's genes. They are motor proteins that move directionally along a nucleic acid phosphodiester backbone, separating two annealed nucleic acid strands (i.e., DNA, RNA, or RNA-DNA hybrid) using energy derived from ATP hydrolysis. There are many helicases resulting from the great variety of processes in which strand separation must be catalyzed. Approximately 1% of eukaryotic genes code for helicases.[1] In humans, 95 non-redundant helicases are coded for in the genome, 64 RNA helicases and 31 DNA helicases.[2] Many cellular processes, such as DNA replication, transcription, translation, recombination, DNA repair, and ribosome biogenesis involve the separation of nucleic acid strands that necessitates the use of helicases.
 KEEFE ET AL" Bloom syndrome occurs most frequently in the Ashkenazi Jewish population with patients almost exclusively homozygous for a frameshift mutation resulting from a 6 bp deletion/7 bp insertion at nucleotide 2,281 (BLMAsh). This mutation causes premature termination of the encoded gene product producing a truncated protein of 739 amino acids while the full length protein contains 1417 amino acids.
The mutated gene in Bloom syndrome, BLM, was localized to chromosome 15q26.1 and encodes a member of the RecQ family of DNA helicases. This family also contains several other genes that are associated with disease phenotypes including the Werner Syndrome protein (WRN) and the defective protein in Rothmund-Thomson syndrome (RecQL4). Both of these diseases also feature an increased incidence of cancer. BLM, along with the rest of the members of this family, exhibits 3'-5' helicase activity and plays a role in DNA repair and recombination. BLM functions during replication stress and is required for the recruitment of several other important repair proteins including NBS1, BRCA1, Rad51 and MLH1. In addition, the BLM helicase is involved in recombinational repair events as evidenced by its ability to promote branch migrations of Holliday junctions at stalled replication forks. BLM may also play a role in apoptosis since it directly interacts with p53 and helps regulate its transcriptional activity."
=========================================================================

3.ATM gene
Ataxia telangiectasia mutated
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ataxia telangiectasia mutated
Identifiers
Symbols ATM; AT1; ATA; ATC; ATD; ATDC; ATE; TEL1; TELO1
External IDs OMIM607585 MGI107202 HomoloGene30952 ChEMBL: 3797 GeneCards: ATM Gene
EC number 2.7.11.1
Orthologs
Species Human Mouse
Entrez 472 11920
Ensembl ENSG00000149311 ENSMUSG00000034218
UniProt Q13315 Q62388
RefSeq (mRNA) NM_000051 NM_007499
RefSeq (protein) NP_000042 NP_031525
Location (UCSC) Chr 11:
108.09 – 108.24 Mb
Chr 9:
53.44 – 53.54 Mb

PubMed search [1] [2]
Ataxia telangiectasia mutated (ATM) is a serine/threonine protein kinase that is recruited and activated by DNA double-strand breaks. It phosphorylates several key proteins that initiate activation of the DNA damage checkpoint, leading to cell cycle arrest, DNA repair or apoptosis. Several of these targets, including p53, CHK2 and H2AX are tumor suppressors.
The protein is named for the disorder Ataxia telangiectasia caused by mutations of ATM.[1]

GOLDGAR ET AL suggested:

"The risk estimates from this study suggest that women carrying the pathogenic variant, ATM c.7271T > G, or truncating mutations demonstrate a significantly increased risk of breast cancer with a penetrance that appears similar to that conferred by germline mutations in BRCA2."

=============================================================

4. MRE 11 gene

MRE11A

From Wikipedia, the free encyclopedia
Jump to: navigation, search
MRE11 meiotic recombination 11 homolog A (S. cerevisiae)
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols MRE11A; ATLD; HNGS1; MRE11; MRE11B
External IDs OMIM600814 MGI1100512 HomoloGene4083 GeneCards: MRE11A Gene
RNA expression pattern
PBB GE MRE11A 205395 s at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 4361 17535
Ensembl ENSG00000020922 ENSMUSG00000031928
UniProt P49959 Q61216
RefSeq (mRNA) NM_005590 NM_018736
RefSeq (protein) NP_005581 NP_061206
Location (UCSC) Chr 11:
94.15 – 94.23 Mb
Chr 9:
14.78 – 14.84 Mb

PubMed search [1] [2]
Double-strand break repair protein MRE11A is a protein that in humans is encoded by the MRE11A gene.[1]
This gene encodes a nuclear protein involved in homologous recombination, telomere length maintenance, and DNA double-strand break repair. By itself, the protein has 3' to 5' exonuclease activity and endonuclease activity. The protein forms a complex with the RAD50 homolog; this complex is required for nonhomologous joining of DNA ends and possesses increased single-stranded DNA endonuclease and 3' to 5' exonuclease activities. In conjunction with a DNA ligase, this protein promotes the joining of noncomplementary ends in vitro using short homologies near the ends of the DNA fragments. This gene has a pseudogene on chromosome 3. Alternative splicing of this gene results in two transcript variants encoding different isoforms.[2]

Interactions

MRE11A has been shown to interact with Ku70,[3] Ataxia telangiectasia mutated,[4][5] MDC1,[6] Rad50,[3][5][7][8][9] Nibrin,[5][9][10][11][12] TERF2[13] and BRCA1.[5][7][14][15]

 FUKUDA ET AL

"MRE11, RAD50, and XRS2 have been identified in yeast as components of the HR and NHEJ pathways (4) . A physical complex with these proteins has been identified. In vertebrates, MRE11 and RAD50 form a complex with NBS1, whose mutation causes NBS (5 , 6) . The clinical features of NBS overlap with those of AT. They are characterized by chromosome instability, increased hypersensitivity to ionizing radiation, immunodeficiency, and predisposition to cancer. AT is caused by mutations in the ATM gene, which encodes a protein kinase homologous with phosphatidylinositol-3 kinase (7) . ATM is a key regulator of the cellular response to DSBs. NBS1 is phosphorylated in an ATM-dependent manner after ionizing radiation, suggesting a link between ATM and NBS1 in a common signaling pathway (8) . MRE11 phosphorylation upon DNA damage is dependent on NBS1 (9) . Therefore, it is highly likely that MRE11 participates in the same pathway in response to DNA damage. Consistent with this functional interaction, hypomorphic mutations in the MRE11 gene cause ataxia-telangiectasia-like disorder, the phenotypes of which are indistinguishable from those of AT (10) ."

 ATM mutations play a causal role in AT and have been demonstrated in lymphoid malignancies
======================================================================

5.  RAD51
From Wikipedia, the free encyclopedia
Jump to: navigation, search
RAD51 homolog (S. cerevisiae)

A filament of Rad51 based on PDB 1SZP.[1]
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols RAD51; BRCC5; HRAD51; HsRad51; HsT16930; MRMV2; RAD51A; RECA
External IDs OMIM179617 MGI97890 HomoloGene2155 GeneCards: RAD51 Gene
RNA expression pattern
PBB GE RAD51 205024 s at tn.png
PBB GE RAD51 205023 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 5888 19361
Ensembl ENSG00000051180 ENSMUSG00000027323
UniProt Q06609 Q08297
RefSeq (mRNA) NM_001164269 NM_011234
RefSeq (protein) NP_001157741 NP_035364
Location (UCSC) Chr 15:
40.99 – 41.02 Mb
Chr 2:
119.11 – 119.15 Mb

PubMed search [1] [2]
"RAD51 is an eukaryote gene. The protein encoded by this gene is a member of the RAD51 protein family which assist in repair of DNA double strand breaks. RAD51 family members are homologous to the bacterial RecA and yeast Rad51. The protein is highly conserved in most eukaryotes, from yeast to humans.
BRCA genes

This protein can interact with the ssDNA-binding protein RPA, BRCA2, PALB2[3] and RAD52.
The structural basis for Rad51 filament formation and its functional mechanism still remain poorly understood. However, recent studies using fluorescent labeled Rad51[4] has indicated that Rad51 fragments elongate via multiple nucleation events followed by growth, with the total fragment terminating when it reaches about 2 μm in length. Disassociation of Rad51 from dsDNA, however, is slow and incomplete, suggesting that there is a separate mechanism that accomplishes this."

"The RAD51 gene family, genetic instability and cancer.

Source

Medical Research Council, Radiation and Genome Stability Unit, Harwell, Oxfordshire OX11 0RD, UK. j.thacker@har.mrc.ac.uk

Abstract

Inefficient repair or mis-repair of DNA damage can cause genetic instability, and defects in some DNA repair genes are associated with rare human cancer-prone disorders. In the last few years, homologous recombination has been found to be a key pathway in human cells for the repair of severe DNA damage such as double-strand breaks. The RAD51 family of genes, including RAD51 and the five RAD51-like genes (XRCC2, XRCC3, RAD51L1, RAD51L2, RAD51L3) are known to have crucial non-redundant roles in this pathway."---------------------------------------------------------------------

THE BRCA ITSELF TO WORK NEED A BUNCH OF VARIOUS COFACTORS CALLED  FANCB-Related Fanconi Anemia, FANCC-Related Fanconi Anemia, FANCD2-Related Fanconi Anemia, FANCE-Related Fanconi Anemia, FANCF-Related Fanconi Anemia, FANCG-Related Fanconi Anemia, FANCI-Related Fanconi Anemia, FANCL-Related Fanconi Anemia, FANCM-Related Fanconi Anemia, PALB2-Related Fanconi Anemia, RAD51C-Related Fanconi Anemia, SLX4-Related Fanconi Anemia (ALTER ET AL!)

========================================================================
IN OTHER NEWS...

HPV Vaccine: 2 Doses as Good as 3 Doses in Young Women

Troy Brown.  go to article!
IMPLICATIONS OF TARGET THERAPY ON BONE MARROW FAILURE SYNDROMES:

As we move forward, and with the increase of therapeutic agents available in our armamentarium, the focus of therapy in bone marrow failure syndrome will be on the gene altered rather then putting these disease in a global group.  Indeed a Myelodysplastic Syndrome driven by alteration of gene repair mechanisms (BRCA or RAD51) should not be treated as a Ribosomal derangement or a change in a gene that induce morphogenic changes (Dyskeratosis Congenita).  We know by now that PARP inhibitors have a better chances theoritically to act BRCA alterations then immunomodulators (Thalidomid, Revlimid) which should be attempted in Dyskeratosis like syndrome.
We know now that marrow failure syndromes particularly the congenital one have failure or gene alterations in the following targets:

1. Co-factors to DNA repair genes (Fanconi Anemia) (PARP inhibitor)
2. Telomere biology (may be the MTOR inhibitor)
3. Morphogenesis  (Revlimid, Thalidomid, Anti MEK)
4. Receptors of growth factors (Erythropoietin, thrombopoietin ) (MPL gene) (Interferon)
5. Ribosomal biogenesis (antibiotics)
6. Histone  (Acetyl transferaseinhibitor)
7. Mitochondrial Gene (MTOR Inhibitor)

Proof of concept is still needed in some cases
but that this is the way to go, we need more discernment
MDS, first obtain gene altered and make a therapeutic decision!